Aligos Therapeutics Announces Five Abstracts Accepted for Presentation at The Liver Meeting® 2026

Aligos Therapeutics (Nasdaq: ALGS) announced acceptance of five abstracts for presentation at The Liver Meeting, held November 5–9, 2026, in Denver.

Rhea-AI Summary

Aligos Therapeutics (Nasdaq: ALGS) announced acceptance of five abstracts for presentation at The Liver Meeting, held November 5–9, 2026, in Denver.

Three abstracts cover pevifoscorvir sodium in chronic hepatitis B, including immune effects, hepatitis B surface antigen levels and laboratory testing. Another covers the preclinical profile of ALG-170675, and the fifth addresses ALG-215007 inhibition of hepatitis delta virus replication. The hepatitis B presentations are scheduled for November 8; the hepatitis delta presentation is scheduled for November 7. The abstracts are available on the AASLD website.

Key Figures

Accepted abstracts: 5 abstracts HBsAg level: <3,000 IU/mL

Accepted abstracts

5 abstracts

Accepted for presentation at The Liver Meeting 2026

HBsAg level

<3,000 IU/mL

Abstract title; HBeAg-positive subjects with chronic HBV following long-term on-study treatment

Key Terms

hbv, hbeag, antisense oligonucleotide, pharmacokinetics

4 terms

hbv medical

"chronic hepatitis B virus (HBV) infection"

HBV stands for hepatitis B virus, a contagious virus that infects the liver and can cause both short-term illness and long-term liver damage. For investors, HBV matters because diagnostics, vaccines and treatments aimed at preventing or managing the infection can create sizable markets and regulatory milestones; think of it like a widespread problem that creates demand for tools and medicines, where successful products can materially affect a company’s revenue and valuation.

hbeag medical

"HBeAg-positive patients with chronic hepatitis B infection"

HBeAg is a protein made by the hepatitis B virus that shows the virus is actively reproducing in the body; doctors test for it to assess how contagious or active an infection is. For investors, HBeAg status matters because it is a common clinical trial endpoint and regulatory marker — like a dashboard light showing whether a treatment is suppressing the virus — and therefore influences drug development prospects, approval decisions, and market potential for therapies.

antisense oligonucleotide medical

"Potential best-in-class antisense oligonucleotide (ASO)"

An antisense oligonucleotide is a small piece of synthetic genetic material designed to attach to specific molecules in the body’s cells, effectively blocking or modifying how genes are expressed. This technology is important because it can be used to develop targeted treatments for certain diseases, which may influence the value of biotech companies and the broader healthcare sector. Its development reflects advances in personalized medicine and gene-based therapies.

pharmacokinetics medical

"efficacy in an AAV-HBV mouse model, pharmacokinetics and safety"

Pharmacokinetics is the study of how a substance, such as a drug or chemical, moves through and is processed by the body over time. It tracks how it is absorbed, distributed, broken down, and eventually eliminated. For investors, understanding pharmacokinetics helps gauge the effectiveness, safety, and potential risks of new medications or treatments, which can influence a company’s success and valuation in the healthcare industry.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SOUTH SAN FRANCISCO, Calif., Oct. 05, 2026 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced five abstracts have been accepted for presentation at the American Association for the Study of Liver Disease’s (AASLD) The Liver Meeting^® 2026, being held November 5 – 9, 2026 in Denver, CO. The abstracts released today can be found on the AASLD website at https://www.aasld.org/the-liver-meeting.

Details on the abstracts are as follows:

Pevifoscorvir sodium: Potential first-/best-in-class small molecule CAM-E for chronic hepatitis B virus (HBV) infection

Abstract #: 4139
Title: Immune-modulatory effects of pevifoscorvir sodium in HBeAg-positive patients with chronic hepatitis B infection
Presenter: Professor Lung-Yi Loey Mak, MBBS(HK), MD(HK), MRCP(UK), PDipID (HK), FHKCP, FHKAM (Medicine), FRCP (Glasg), FRCP (Edin), FRCP, Clinical Assistant Professor at The University of Hong Kong
Date/Time: November 8, 2026 at 1:00pm – 2:00pm MT
Session: Hepatitis B ("4001-4193"); Poster of Distinction

Abstract #: 4142
Title: Pevifoscorvir Sodium Reduces HBsAg Levels to < 3000 IU/mL in HBeAg Positive Subjects with Chronic HBV Infection Following Long-Term On-Study Treatment
Presenter: Professor Man-Fung Yuen, MBBS, MD, PhD, DSc, Chair and Chief of the Division of Gastroenterology and Hepatology, University of Hong Kong
Date/Time: November 8, 2026 at 1:00pm – 2:00pm MT
Session: Hepatitis B ("4001-4193")

Abstract #: 4158
Title: Pevifoscorvir Sodium (CAM-E) is Superior to Nucleos(t)ide Analogs in Suppressing Hepatitis B Virus Double-stranded Linear DNA In Vitro
Presenter: Andreas Jekle, PhD
Date/Time: November 8, 2026 at 1:00pm – 2:00pm MT
Session: Hepatitis B ("4001-4193")

ALG-170675: Potential best-in-class antisense oligonucleotide (ASO) for chronic hepatitis B virus (HBV) infection

Abstract #: 4156
Title: The potentially best-in-class HBV ASO ALG-170675 demonstrates a favourable preclinical profile: efficacy in an AAV-HBV mouse model, pharmacokinetics and safety in mouse and monkey
Presenter: Jin Hong, PhD
Date/Time: November 8, 2026 at 1:00pm – 2:00pm MT
Session: Hepatitis B ("4001-4193")

Preclinical

Abstract #: 3224
Title: Potent Inhibition of Hepatitis Delta Virus Replication by the Antisense Oligonucleotide ALG-215007
Presenter: Kellan Passow, PhD
Date/Time: November 7, 2026 at 1:00pm – 2:00pm MT
Session: Hepatitis - Other Infections ("3195-3246")

About Aligos

Aligos Therapeutics, Inc. (NASDAQ: ALGS) is a clinical stage biotechnology company founded with the mission to improve patient outcomes by developing best-in-class therapies for the treatment of liver and viral diseases. Aligos applies its science driven approach and deep R&D expertise to advance its purpose-built pipeline of therapeutics for high unmet medical needs such as chronic hepatitis B virus infection.

For more information, please visit www.aligos.com or follow us on LinkedIn or X.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Any statements in this press release that are not historical facts may be considered “forward-looking statements,” including without limitation, statements regarding Aligos’ plans to advance its pipeline and develop best-in-class therapies for the treatment of liver and viral diseases. Such forward looking statements are subject to substantial risks and uncertainties that could cause our development programs, future results, performance, or achievements to differ materially from those anticipated in the forward-looking statements. Such risks and uncertainties include, without limitation, risks and uncertainties inherent in the drug development process, including Aligos’ clinical-stage of development, the process of designing and conducting clinical trials, the regulatory approval processes, and other matters that could affect the sufficiency of Aligos’ capital resources to fund operations. For a further description of the risks and uncertainties that could cause actual results to differ from those anticipated in these forward-looking statements, as well as risks relating to the business of Aligos in general, see Aligos’ Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on August 6, 2026 and its future periodic reports to be filed or submitted with the Securities and Exchange Commission. Except as required by law, Aligos undertakes no obligation to update any forward-looking statements to reflect new information, events or circumstances, or to reflect the occurrence of unanticipated events.

Investor Contact
Aligos Therapeutics, Inc.
Jordyn Tarazi
Vice President, Investor Relations & Corporate Communications
+1 (650) 910-0427
jtarazi@aligos.com